This Stock Is Up 704% in 2025 But Has No Products to Its Name

Company Overview - Relmada Therapeutics (RLMD) is a clinical-stage pharmaceutical company with a market capitalization of $141 million and no commercialized products [4] - The company has been focused on product acquisition opportunities after discontinuing studies of its lead candidate in 2024 [4] Technical Performance - RLMD has shown strong technical momentum, gaining 440% since August 28, when a new "Buy" signal was issued by Trend Seeker [2][4] - The stock recently reached a new 52-week high of $5.21 during intraday trading on November 19 [3] - The stock has a 100% "Buy" technical opinion from Barchart, indicating strong market sentiment [4][5] Financial Metrics - Over the past year, RLMD's stock has gained 40.3%, and it has increased by 703.85% year-to-date [5] - The stock recently traded at $4.18, with a 50-day moving average of $2.34 [5] - The company has made 16 new highs and gained 107.96% in the last month [5] Technical Indicators - RLMD has a Weighted Alpha of +214.41, reflecting strong price performance [5] - The Relative Strength Index (RSI) is at 78.08, suggesting the stock may be overbought [5] - There is a technical support level around $3.79, which may provide a cushion against price declines [5]